Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
Ying-Chun ShenTsung-Hao LiuAlan NicholasAkihiko SoyamaChang-Tsu YuanTse-Ching ChenSusumu EguchiTomoharu YoshizumiShinji ItohNoriaki NakamuraHisashi KosakaMasaki KaiboriTakamichi IshiiEtsuro HatanoChikara OgawaAtsushi NaganumaSatoru KakizakiChih-Hsien ChengPo-Ting LinYung-Yeh SuChien-Huai ChuangLi-Chun LuChi-Jung WuHung-Wei WangKun-Ming RauChih-Hung HsuShi-Ming LinYi-Hsiang HuangSairy HernandezRichard S FinnMasatoshi KudoAnn-Lii ChengPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision.